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We have used a short-term transfection technique, in which we monitor the ability of DNA fragments to 
induce the expression of the chloramphenicol acetyltransferase (CAT) gene in rat 208F fibroblast cells. Us- 
ing appropriate vectors we have assayed for promoter or enhancer activity of the 0.8 kb SstI fragment lo- 
cated within the Y-flanking sequences of the first coding exon of the human T24 and normal Ha-rarl genes. 
We find that this fragment contains promoter and enhancer activities in both the normal and the T24 Ha- 
rasl gene. 
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1. INTRODUCTION 
The ras gene family play an important role in the 
development of cancer (review [l]) and have 
therefore recently been the subject of extensive 
structural studies. The nucleotide sequences of the 
Ha-ras, Ki-ros and N-rus structural genes, introns 
and extragenic regions have been previously 
reported [ 11. Nevertheless, the structural studies by 
themselves cannot explain the subtleties of gene ex- 
pression and regulation during growth and 
development. The identification of regulatory se- 
quences, such as promoters, enhancers, transcrip- 
tional initiation sites, binding sites for regulatory 
proteins, and RNA processing sites require the use 
of in vivo or in vitro assays for gene expression. 
One type of DNA sequence, the transcriptional 
regulatory elements termed enhancers, are cis- 
acting elements which have a positive effect on the 
transcription of nearby genes (review [2]). 
Enhancers might be expected to be found in genes 
that are constitutively expressed at high levels or 
genes that can be readily induced. The rus genes 
are known to be constitutively expressed in all 
tissues examined [3,4] and at high levels in some 
normal tissues [5] and tumors [6-91. 
The location of transcriptional start sites has 
recently been determined in Ha-rasl [lo] and N-ras 
[l 1) genes using primer extension and Si mapping 
techniques, respectively. A non-coding exon at the 
5 ‘-end of the Ha-ras [lo] and N-ras [l l] gene has 
been found, but no obvious TATA box exists in 
the expected promoter region although there are 
several CCGCCC and their inverted complement 
GGGCGG sequences nearby [lo]. The sequence 
GGGCGG represents the core consensus for the 
eukaryotic RNA polymerase Spl binding sites [ 121. 
Here, we have used an in vitro short-term 
transfection assay to analyze the 5 ‘-region of 
human T24 and normal Ha-rasl genes for the 
presence of promoter or transcriptional enhancer 
sequences. Our data demonstrate the presence of 
promoters and enhancers within the 0.8 kb SstI 
fragments at the 5’-end of the structural Ha-rasl 
gene. 
2. MATERIALS AND METHODS 
2.1. Construction of recombinant plasmids 
The organization of the human Ha-rasl gene 
with particular emphasis on the 5 ’ - and flanking 
sequences is shown in fig. 1. The 853 or the 847 bp 
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Fig. 1. Organization of the human Ha-rusl gene. The 
coding sequences are designated by black boxes and the 
non-coding 5’sequences by open boxes. The locations 
of the sequence GGGCGG and its complementary 
CCGCCC contained between nucleotides 220 and 576 of 
the map and situated at the 5’-end of the Ha-rasl gene 
are shown. Transcriptional start sites are indicated by 
arrows. DEL, deletion; B, BarnHI; S, WI; Xm, 
XmaIII; N, MzeI; I, II, III and IV, coding exons; Ia, 
non-coding exon. 
WI fragment from the normal or the T24 Ha-rasl 
gene respectively [13,14] containing the un- 
translated exon [lo] was assayed. 
Plasmid pCAT12 was constructed by inserting a 
0.9 kb BarnHI-XbaI fragment from plasmid 
pLW4 [15] into a BarnHI-XbaI digest of plasmid 
pUC12 (obtained from BRL). The 0.9 kb BumHI- 
XbaI fragment carries the structural CAT gene and 
the 3 ’ Herpes simplex virus immediate arly 5 gene 
polyadenylation sequences. Plasmids pCATl22A 
and pCAT122B carry the 0.8 kb SstI fragment 
from the normal Ha-rasl and plasmids pCAT 123A 
and pCAT123B the T24 equivalent fragment from 
the mutant in one or other orientation as indicated 
in fig.2a. Plasmid pTKCMO-11 contains a 726 bp 
EcoRI/SmaI fragment carrying the Moloney 
murine sarcoma virus enhancer and mink se- 
quences obtained from an integrated provirus [16] 
in front of the CAT gene. The Moloney sequences 
are proximal to the CAT sequences and detailed 
construction of this plasmid has been reported in 
[171. 
170 
Plasmid pTKCAT3 was constructed by R. 
Miksicek. The CAT gene and the 3 ’ -polyade- 
nylation sequences from plasmid pSV2-CAT [18] 
were linked to the HSV-1 tk promoter and the 
hybrid gene inserted into the pUC8 vector. 
Plasmids pTKCAT 117A and pTKCATll7B carry 
the normal and plasmids pTKCATl18A and 
pTKCATl18B the T24 0.8 kb SstI fragment in one 
or other orientation as indicated in fig.2b. The 
0.8 kb SstI fragment was first cloned into the SstI 
site in the polylinker of plasmid pIC-20H [19] and 
then excised as a Hind111 fragment and inserted 
into the Hind111 site of pTKCAT3. 
2.2. DNA transfections and CAT assay 
Short-term transfections into rat 208F fibroblast 
cells [20] were performed using a modification [21] 
of the calcium phosphate technique [22]. Cells 
were harvested 45 h post-addition of DNA to the 
cells and the CAT assay was performed from the 
cell extracts as described [ 181. Briefly, each assay 
contained in a volume of 0.15 ml, 0.25 ,uCi 
[14C]chloramphenicol (Amersham) and soluble ex- 
tract containing 60 pg protein as estimated by the 
method of Bradford [23]. After incubation at 
37”C, the reaction products were isolated and 
separated by thin-layer chromatography on silica 
plates using chloroform : methanol (95 : 5) as sol- 
vent. After autoradiography, the acetylated and 
non-acetylated forms of [14C]chloramphenicol 
were scraped off and quantitated by scintillation 
counting. 
3. RESULTS 
To identify putative control signals in the 
5 ’ -flanking sequences of the human Ha-rusl gene, 
we investigated the ability of a 0.8 kb fragment 
located in the 5 ’ -non-coding region of the Ha-rasl 
gene to provide a promoter or enhancer in conve- 
nient vector systems employing the CAT assay. 
The structure of the recombinant plasmids used 
to assay for promoter function is shown in fig.2a. 
The CAT gene lacks a promoter in pCAT12. 
Recombinants pCATl22A and pCAT 122B carry 
the 0.8 kb SstI DNA fragment from the normal 
Ha-r& gene in the same or opposite orientation to 
the CAT gene respectively. Recombinants 
pCAT123A and pCAT123B carry the 0.8 kb SstI 
DNA fragment from the mutant T24 Ha-rusl on- 
Volume 203, number 2 FEBS LETTERS July 1986 
Normal 5 5' Ha-rasl T24 
pCAT122A t----F pCAT123A 
pCAT122B s- 5 l-l pCAT123B 
x_ - ,* 
a 
Normal 
pTKCAT117A 
pTKCATll7B 
b 
Fig.2. Schematic representation of CAT recombinant 
plasmids. (a) Structure of the recombinant plasmids 
used to assay for promoter function. Dashed line, 
pUC12; thin line, human DNA; open box, non-coding 
exon Ia of Ha-rusl; black box, CAT gene; hatched box, 
HSV-2 lE5 gene polyadenylation signal. The maps are 
not drawn to scale. S, SstI; E, EcoRI; B, BumHI; Xb, 
XbaI. (b) Structure of the recombinant plasmids used to 
assay for enhancer function. Sequence representation as 
in a with the following exceptions: hatched box, SV40 
polyadenylation signal; dotted box, HSV-1 tk promoter. 
S, S&I; E, EcoRI; B, BumHI; H, HindIII. 
cogene in the same or opposite orientation to the 
CAT gene, respectively. As positive control we 
used plasmid pTKCMO-11 which contained the 
enhancer from Moloney MSV in plasmid 
pTKCAT3 [17]. 
Recombinant plasmids were introduced into rat 
208F fibroblasts by the calcium phosphate tech- 
nique [22]. 45 h after transfection CAT activity 
was measured in cell extracts. We first optimized 
conditions for efficient measurements of CAT ac- 
tivity. The amount of cell protein per assay was ad- 
justed to 60 pg so that the CAT activity was linear 
for at least 1 h with the recombinants used here. 
Representative results with the plasmids described 
in fig.2a are shown in fig.3a and table 1. Both the 
normal and T24 Ha-rasl sequences stimulated 
CAT activity significantly (l l-16-fold) in both 
orientations. 
The structures of the recombinant plasmids used 
to assay for enhancer function are shown in fig.2b. 
Plasmid pTKCAT3 contains the HSV-1 tk pro- 
moter in front of the CAT gene and is an ap- 
propriate vector for assaying enhancer activ- 
ity [17]. Recombinants pTKCATll7A and 
Rat 208F cells 
Rat 208 F cells 
Fig.3. Chromatograms for typical CAT assays upon 
transfection of rat 208F cells with CAT recombinants. 
(a) Experiment using the recombinants described in 
fig.2a. See section 2 for details. (b) Experiment using the 
recombinants described in fig.2b. See section 2 for 
details. 
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Table 1 Table 2 
Relative values of CAT activity in rat 208F fibroblast 
cells after transfection with CAT recombinant plasmids 
Relative values of CAT activity in rat 208F fibroblast 
cells after transfection with CAT recombinant plasmids 
Recombinant 
plasmid* 
Ha-rasl Orientation CAT activity 
DNA relative to (av + SD)b 
CAT 
Recombinant 
plasmid” 
Ha-rasl Orientation CAT activity 
DNA relative to (av + SD)b 
CAT 
pCAT12 - - 1.0 
pTKCMO- 11 - - 38.1 + 5.9 
pCAT122A normal same 12.0 + 5.9 
pCAT122B normal opposite 16.5 f 3.7 
pCAT123A T24 same 13.4 + 3.6 
pCAT123B T24 opposite 11.0 * 5.7 
pTKCAT3 - - 1.0 
pTKCMO- 11 - - 7.6 k 2.2 
pCATl17A normal same 6.0 + 0.1 
pCATl17B normal opposite 3.2 + 0.8 
pCATl18A T24 same 4.3 + 1.1 
pCAT118B T24 opposite 2.7 + 0.2 
a See fig.2a and section 2 for plasmid constructions 
b Relative values of CAT activity of each plasmid 
compared to the value obtained with pCAT12. The 
value for CAT activity after transfection of 40,~g 
pCAT12 per 2 x106 208F recipient cells was 6.9 x 
10d4 pmol acetylatedlpg protein per 1 h incubation. 
The average and standard deviation from 4 
experiments are given 
pTKCAT117B carry the 0.8 kb SstI DNA frag- 
ment from the normal Ha-rasl gene in the same or 
opposite orientation to the CAT gene, respectively. 
Recombinants pTKCATll8A and pTKCAT 118B 
carry the 0.8 kb SstI DNA fragment from the mu- 
tant T24 Ha-rasl oncogene in the same or opposite 
orientation to the CAT gene, respectively. Recom- 
binant plasmids were introduced into rat 208F 
fibroblasts by the calcium phosphate technique as 
above. Representative results are shown in fig.3b 
and table 2. Both the normal and T24 Ha-rusl se- 
quences stimulated CAT activity significantly 
(2.7-6.9-fold) in both orientations. 
4. DISCUSSION 
In this study we have used a gene transfer tech- 
nique to examine for the presence of transcrip- 
tional regulatory sequences 5’ to the coding region 
of the Ha-rasl gene. With the short-term transfec- 
tion assay employed here using CAT expression as 
an indicator system, we found that the 0.8 kb Sstl 
fragment located about 1 kb at the 5 ’ of the Ha- 
rasl gene contains both promoter and enhancer ac- 
tivities. It is notable that both promoter and 
enhancer functions are exerted when the 0.8 kb 
SstI fragment is inserted in either orientation 
a See fig.2b and section 2 for plasmid constructions 
b Relative values of CAT activity of each plasmid 
compared to the value obtained with pTKCAT3. The 
value for CAT activity after transfection of 40 pg per 
2 x lo6 208F recipient cells was 2.5 x lo3 pmol 
acetylated/pg protein per 1 h incubation. The average 
and standard deviation from 4 experiments are given 
relative to the CAT gene. Further, there is no 
significant difference in promoter and enhancer 
functions between the DNAs from the normal or 
the mutated T24 Ha-r& gene. 
Our results agree with those of Ishii et al. [lo] 
who have found that a 551 bp MeI fragment 
(fig.l), which apart from 95 bp falls within the 
5 ‘-end of the 853 bp SstI fragment used in our 
studies, has promoter activity employing a similar 
CAT assay system. However, Ishii et al. [lo] have 
not examined the promoter activity in the opposite 
orientation or from the T24 Ha-rasl corre- 
sponding fragment. Our results are also the first to 
demonstrate an enhancer activity in the 0.8 kb MI 
fragment. It has been reported previously, 
although no data were provided to support the 
claim, that the 305 bp XmaIII fragment (position 
595-900 in the map, fig.1) may contain a 
transcriptional enhancer since deletion ofthis frag- 
ment reduced the transforming activity of the T24 
oncogene [l]. Since the 305 bp XmaIII fragment is 
contained within the 853 bp MI fragment used in 
our studies this is consistent with our findings. Our 
results, using the CAT assay, clearly demonstrate 
that the enhancer is present in both the T24 and 
normal DNA fragments. However we cannot ex- 
clude the possibility that the slight differences in 
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enhancer activity may reflect the small differences 
in the nucleotide sequences between the normal 
and T24 DNAs. The presence of the positive 
regulatory element found in our studies is also con- 
sistent with previous findings which showed that 
deletion of the 0.8 kb SstI fragment abolished the 
biological activity of the Ha-rasl gene, but replace- 
ment by the HSV-1 enhancer fully restored it [24]. 
Although the nucleotide sequence of the coding 
and extragenic regions of some of the ru.s genes is 
known, the regulation of their expression has not 
been elucidated. Recently, Ishii et al. [lo] using 
primer extension analysis have defined the 
transcriptional start sites for the Ha-rasl gene. As 
shown in fig.1 they found four start sites and a 
non-coding exon (40 bp long) located approx. 
1.0 kb upstream of the known first coding exon. 
Using a CAT assay they also demonstrated a pro- 
moter activity in the 551 bp NaeI DNA fragment 
which contains about 420 bp of DNA upstream of 
the putative transcriptional initiation sites as well 
as 40 bp of the first exon and 90 bp of the first in- 
tron (fig.1). However, no TATA box or CAAT 
box could be found in their expected locations 
(about - 30 and - 80 bp respectively). On the 
other hand, several copies of the CC box 
GGGCGG or its complementary sequence 
CCGCCC were found in the SstI fragment (see 
fig.1 and [13,14]). 
A similarity in high CC content and absence of 
a TATA box has been found between the Ha-rasl 
promoter region with the promoter of some other 
genes involved in cellular growth control such 
as the human EGF receptor, hypoxanthine phos- 
phoribosyltransferase, 3-hydroxy-3-methylglutar- 
yl-CoA reductase and adenosine deaminase [IO]. 
Although the significance of this similarity is not 
known, it is tempting to speculate that expression 
of these genes may be regulated in a similar man- 
ner. The significance of these findings is hard to 
assess completely at present. 
Our findings that the Ha-rasl promoter func- 
tions in both orientations is of special interest since 
this has been thought to be exclusively a property 
of enhancers [2]. A precedent for such an element 
has been provided recently by studies on the 
calcium ionophore-inducible cellular promoter 
which functions as a bidirectional promoter with 
enhancer like properties [25]. An enhancer se- 
quence has also been found in the upstream 5’ of 
the fos proto-oncogene (261. The roles of these 
regulatory sequences in the induction of cancer by 
oncogenes such as Ha-ras are obviously of great 
importance. 
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